<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01896648</url>
  </required_header>
  <id_info>
    <org_study_id>20120021266</org_study_id>
    <nct_id>NCT01896648</nct_id>
  </id_info>
  <brief_title>Sexual Dysfunction in Type 2 Diabetic Women</brief_title>
  <official_title>Sexual Dysfunction in Type 2 Diabetic Women: Study on Prevalence and on Risk</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pavia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>IRCCS Policlinico S. Matteo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pavia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Type 2 diabetes mellitus is becoming an increasingly problem for public health and it is&#xD;
      related with various complications such as sexual problems. The prevalence of erectile&#xD;
      dysfunction has been widely studied in men as a complication of diabetes; the prevalence of&#xD;
      sexual dysfunction in women, instead, has not been well investigated. The aim of this study&#xD;
      is to evaluate the prevalence of sexual dysfunction in type 2 diabetic women using&#xD;
      international validated questionnaires.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In an estimated temporal space of about 3 years, 306 women will be recruited consecutively.&#xD;
&#xD;
      After collection of written informed consent, the following data will be collected:&#xD;
&#xD;
        -  History: type of diabetes, comorbidities, current medication, duration of diabetes and&#xD;
           complications, voluptuary habits such as tobacco smoke (both number of packets/year and&#xD;
           nÂ° packets/day), alcohol consumption, coffee consumption, physical activity.&#xD;
&#xD;
        -  Physical exam, general anthropometric parameters such as weight, height, circumference,&#xD;
           body mass index, waist-hip ratio, and blood pressure.&#xD;
&#xD;
        -  Assessment of glycemic variability (fasting plasma glucose and post-prandial glucose)&#xD;
&#xD;
        -  Each patient will be self-administered Female Sexual Function Index (FSFI) and Female&#xD;
           Sexual Distress Scale (FSDS) questionnaires to assess the prevalence of sexual&#xD;
           dysfunction and Self-Rating Anxiety Scale (SAS) and Self-Rating Depression Scale (SDS)&#xD;
           of Zung for an accurate assessment of the state of anxiety and depression.&#xD;
&#xD;
        -  We will collect blood and urine samples to assess: ematology, glycated hemoglobin,&#xD;
           fasting plasma glucose, fasting plasma insulin, total cholesterol, HDL cholesterol,&#xD;
           triglycerides, LDL cholesterol, creatinine, urea, transaminases, electrolytes, complete&#xD;
           urinalysis, 24-hour microalbuminuria, homocysteine, high sensitivity C-reactive protein&#xD;
           (hs-CRP), metalloproteinase-2 (MMP-2), metalloproteinase-9 (MMP-9), soluble adhesion&#xD;
           molecules (sICAM-1, sVCAM-1), sE-selectin, lipoprotein (a) [Lp (a)], Plasminogen&#xD;
           Activator Inhibitor-1 (PAI-1).&#xD;
&#xD;
        -  We will also conduct a clinical and instrumental exam of the foot using Neuropad,&#xD;
           recently validated as a screening tool for diabetic neuropathy. Patients will also&#xD;
           undergo autonomic tests (deep breathing, lying to standing, Valsalva maneuver, and&#xD;
           orthostatic hypotension).&#xD;
&#xD;
      We will also evaluate the presence of neuropathy through the administration of the Michigan&#xD;
      Neuropathy Screening Instrument (MNSI) and the Neuropathy Disability Score (NDS).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
  </study_design_info>
  <primary_outcome>
    <measure>Female Sexual Function Index (FSFI)</measure>
    <time_frame>12 months</time_frame>
    <description>Female Sexual Function Index (FSFI) is a 19-item questionnaire, developed as a brief, multidimensional self-report instrument for assessing the key dimensions of sexual function in women.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prevalence of sexual dysfunction risk factors</measure>
    <time_frame>36 months</time_frame>
    <description>We will consider the following risk factors:&#xD;
Smoking status; Consume of alcohol; Obesity; Hepatic steatosis; Hypertension; Dyslipidemia; Chronic ischemic disease; Hyperuricemia; Chronic kidney disease; Retinopathy; Neuropathy; Vasculopathy.&#xD;
Correlations between sexual dysfunction and single risk factors will be analyzed using the Pearson correlation coefficient r.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Correlation between sexual dysfunction and diabetic neuropathy</measure>
    <time_frame>36 months</time_frame>
    <description>The presence of diabetic neuropathy will be assessed using dysautonomic tests (deep breathing, lying to standing, Valsalva maneuver e orthostatic hypotension).&#xD;
The prevalence of symmetric distal neuropathy will be assessed using:&#xD;
the Neuropad test, developed as a simple visual indicator test to evaluate diabetic neuropathy&#xD;
the Michigan Neuropathy Screening Instrument (MNSI)&#xD;
the Neuropathy Disability Score (NDS) The correlation will be analyzed using the Pearson correlation coefficient r</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">306</enrollment>
  <condition>Sexual Dysfunction</condition>
  <condition>Neuropathy</condition>
  <arm_group>
    <arm_group_label>Type 2 diabetic women</arm_group_label>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      The following parameters will be assessed:&#xD;
&#xD;
      Blood: ematology, glycated hemoglobin, fasting plasma glucose, fasting plasma insulin, total&#xD;
      cholesterol, HDL cholesterol, triglycerides, LDL cholesterol, creatinine, urea,&#xD;
      transaminases, electrolytes, homocysteine, high sensitivity C-reactive protein (hs-CRP),&#xD;
      metalloproteinase-2 (MMP-2), metalloproteinase-9 (MMP-9), soluble adhesion molecules&#xD;
      (sICAM-1, sVCAM-1), sE-selectin, lipoprotein (a) [Lp (a)], Plasminogen Activator Inhibitor-1&#xD;
      (PAI-1).&#xD;
&#xD;
      Urine: complete urinalysis, 24-hour microalbuminuria&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Type 2 diabetic women&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  type 2 diabetes mellitus&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  previous surgery for hysterectomy or ovariectomy&#xD;
&#xD;
          -  hormone replacement&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giuseppe Derosa, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IRCCS Policlinico S. Matteo</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Giuseppe Derosa, MD, PhD</last_name>
    <email>giuseppe.derosa@unipv.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pamela Maffioli, MD</last_name>
    <email>pamelamaffioli@hotmail.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>IRCCS Policlinico S. Matteo Foundation</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giuseppe Derosa, MD, PhD</last_name>
      <email>giuseppe.derosa@unipv.it</email>
    </contact>
    <contact_backup>
      <last_name>Pamela Maffioli, MD</last_name>
      <email>pamelamaffioli@hotmail.it</email>
    </contact_backup>
    <investigator>
      <last_name>Giuseppe Derosa, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pamela Maffioli, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <study_first_submitted>June 25, 2013</study_first_submitted>
  <study_first_submitted_qc>July 6, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2013</study_first_posted>
  <last_update_submitted>July 6, 2013</last_update_submitted>
  <last_update_submitted_qc>July 6, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 11, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pavia</investigator_affiliation>
    <investigator_full_name>Giuseppe Derosa</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

